News for Schrödinger, Inc. (SDGR)

Schrödinger (SDGR) stock fell after Phase 1 trial data for SGR-1505 its experimental drug for B-cell malignancies. Read more here.

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc. (”œSchrödinger” or the ”œC

PR NewswireNEW YORK, June 7, 2025 NEW YORK, June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc.

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc. (”œSchrödinger” or the ”œ

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Schrödinger, Inc. (”œSchrödinger” or the ”œ

Schrödinger, Inc. (Nasdaq: SDGR) today announced the grant of inducement equity awards to the company's newly appointed EVP, Chief Commercial Officer, Global

[url="]Schrödinger[/url], Inc. (Nasdaq: SDGR) today announced the expansion of its leadership team with the appointment of Mannix Aklian as executive vice pre

Mannix Aklian appointed as Executive Vice President and Chief Commercial Officer of Schrödinger, Inc. (SDGR). Aklian to lead global software sales and

Schrödinger, Inc. (Nasdaq: SDGR) today reported that on May 21, 2025, the company granted restricted stock units (RSUs) with respect to 7,051 shares of the co

[url="]Schrödinger[/url], Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conferenc

Schrödinger, Inc. (SDGR) to participate in Jefferies Global Healthcare Conference on June 4, 2025. The live webcast will be available in the ”œInvesto

On May 20, Schrödinger, Inc. (NASDAQ:SDGR) announced the departure of Chief Financial Officer Geoffrey Porges, MBBS., who is stepping down to pursue other opportunities. Richie Jain, previously Senior Vice President of Strategic Finance and Head of Corporate and Business Development, will succeed him. Dr. Porges will continue as an advisor until June 6, 2025, to […]

Schrodinger delivers strong Q1 results, driven by software growth and evolving FDA regulations. Read more to see why SDGR stock is a Buy.

[url="]Schrödinger[/url], Inc. (Nasdaq: SDGR) today announced that initial Phase 1 clinical data for SGR-1505, its investigational MALT1 inhibitor, will be pr

Schrödinger (SDGR) to present Phase 1 data on MALT1 inhibitor SGR-1505. Presentations at EHA Annual Congress and International Conference on Malignant

Schrödinger, Inc. reports strong Q1 2025 performance with 63% revenue growth, advancements in predictive toxicology, and promising clinical updates.

Schrödinger, Inc. (NASDAQ:SDGR) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ETCompany ParticipantsJaren Madden - Senior Vice President, Investor...

The following slide deck was published by Schrödinger, Inc.

PR NewswireVANCOUVER, BC, May 5, 2025 Equity Insider News CommentaryIssued on behalf of Avant Technologies Inc.VANCOUVER, BC, May 5, 2025 /PRNewswire/ --Th